NASDAQ:MIRM

Mirum Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy MIRM

*Your capital is at risk

$111.07

+3.30 (+3.06%)

At Close: Jun 23, 2026

Mirum Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -27.85. In total, the insiders bought 882.99K and sold 140.14K MIRM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-27.85
● Buy	882.99K shares
● Sell	140.14K shares
76% Buy Activity Weak Positive Correlation
Buy Signal Low Confidence Jan 28, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -27.85. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (76% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 17, 2026 Sell	Common Stock S-Sale	Howe Jolanda SVP, Global Controller	Officer	2 594 Value: $264.5K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Brege Laura Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Heron Patrick J Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Heron Patrick J Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Fischer Laurent Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Grey Michael G Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Walbert Timothy P Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Walbert Timothy P Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Cardon Lon Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Cardon Lon Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Fairey William Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Fairey William Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Ramasastry Saira Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Ramasastry Saira Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Grey Michael G Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Fischer Laurent Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Brege Laura Director	Director	3 772 Value: $381.0K
Jun 09, 2026 Buy	Common Stock M-Exempt	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	2 393 Value: $63.4K
Jun 09, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	2 393 Value: $63.4K
Jun 08, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	2 258 Value: $209.6K
Jun 08, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	1 175 Value: $110.4K
Jun 08, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	1 567 Value: $149.1K
Jun 05, 2026 Buy	Common Stock M-Exempt	Radovich Peter President And COO	CEO / President	16 988 Value: $326.0K
Jun 05, 2026 Buy	Stock Option (right to buy) M-Exempt	Radovich Peter President And COO	CEO / President	16 988 Value: $326.0K
Jun 01, 2026 Sell	Common Stock S-Sale	Peetz Christopher Chief Executive Officer	CEO / President	2 602 Value: $246.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MIRUM PHARMACEUTICALS, INC.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...

Read Full Profile Here